Aarey Drugs & Pharmaceuticals Limited

NSE: AAREYDRUGSPharmaceuticalsASM stage 1

Share price

₹103.89

-4.52% close of 8 Oct 2026

Market cap ₹330 CrP/E 79.1

Price-based ratios (P/B, dividend yield, EV/EBITDA) are as of 7 Oct 2026, the close above is 8 Oct 2026.

Business score

How strong the business is, in one number. The parts behind it are in Pro.

out of 100 · worked out 8 Oct 2026

Your ratios

The numbers you want to see first. Tap Edit to change them.

Market cap

₹330 Cr

P/E ratio

79.1

P/B ratio

2.0

ROCE

5.6%

ROE

2.8%

Dividend yield

0.0%

Price & valuation chart

How the share price and its valuation have moved. Hover over the chart to see any day. Prices as of the last close.

Prices as of 8 Oct 2026 close52-week high ₹108.8152-week low ₹50.75

Answers

Simple answers to the questions investors ask most, from the company's own numbers.

How fast it has been growing

Sales fell 7.7% over the past year. Meanwhile what it keeps of every 100 rupees of sales held steady, near 1.7% over the last four years.

Whether it grew faster than its sector

It grew 18.0% a year against a sector median of 13.1% — 5.0 percentage points faster.

Room to re-rate, or risk of de-rating

At 79.1× earnings it costs 3.3× the market, which pays 23.9× across 2199 companies we can price. Its own industry sits at 84.2×, across 4 companies. It is against its own five-year median of 32.4×, the 98th percentile of its own range.

Whether growth justifies the valuation

Priced at 39.5 times its growth rate, on earnings growth of 2%.

	Profit growth	Price per ₹1 profit	Per 1% growth
Aarey Drugs & Pharmaceuticals Limited — this one	2%/yr	79.1×	₹39.5
Wockhardt Limited	43%/yr	82.4×	₹1.9
Sai Life Sciences Limited	227%/yr	85.9×	—
Neuland Laboratories Limited	30%/yr	54.7×	₹1.8
Piramal Pharma Limited	-31%/yr	—	—
Rubicon Research Limited	155%/yr	90.3×	—

Compared with companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

How it compares with its peers

Against companies the exchange files under the same label (Pharmaceuticals), it ranks 100 of 130 on returns, 25 of 127 on growth, 119 of 130 on margin. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

What makes it hard to beat — and is that still true?

No durable advantage shows in the numbers: it earns 5.6% on capital, ahead of 23% of companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

Whether its growth pays for itself

No — Over the last five years it made ₹16 crore of cash from the business but spent ₹21 crore on plant and equipment, ₹5 crore more than it made; the gap was mostly borrowed — borrowings rose from ₹14 crore to ₹50 crore. But only about 26 of every 100 rupees of profit it reported over 12 years arrived as cash — the rest is tied up. Its cash comes back more slowly than it used to: it went from being waiting 68 days for its cash to waiting 90 days for its cash.

Profit reality check

Is the profit real cash? Simple checks on the accounts. Facts only, not advice.

6 of 9 checks clear · 67%

Latest result · Q1 FY27

What the last results showed. Whether management kept its word is in Pro.

Announced 14 Aug 2026 · Standalone · Unaudited

Revenue

₹45 Cr

Revenue vs last year

-56.3%

Revenue vs last quarter

-76.4%

Net profit

₹1 Cr

Profit vs last year

-25.3%

Profit vs last quarter

-34.4%

Net margin

2.3%

EPS

₹0.36

Checklist before you investPRO

Points for and against, in one list.

Key numbers & peers

The main numbers grouped by topic, and how the company compares with similar ones.

Price

Market cap: ₹330 Cr
Prev close: ₹103.89
52w High: ₹110
52w Low: ₹50.3
Enterprise value: ₹380 Cr
Beta: 1.2
Price CAGR 1y: 30.0%
Price CAGR 3y: 34.0%
Price CAGR 5y: 24.0%
Price CAGR 10y: 9.0%

Ratios

Return on assets: 1.3%
PEG ratio: 39.6
P/E ratio: 79.1
P/B ratio: 2.0
EV / EBITDA: 54.3
Industry P/E: 38.0
ROCE: 5.6%
ROCE 5y average: 6.8%
ROE: 2.8%
Debt / Equity: 0.3
Interest coverage: 2.0
Dividend yield: 0.0%
ROE 3y average: 3.0%
ROE last year: 3.0%

Annual P&L

Annual revenue: ₹472 Cr
Annual profit: ₹4 Cr
Operating margin: 1.5%
Net profit margin: 0.8%
EBITDA margin: 1.5%
Sales growth 3y: 4.1%
Sales growth 5y: 6.3%
Profit growth 3y: 2.0%
Profit growth 5y: -9.0%
EPS: ₹1.4
Sales growth TTM: -8.0%
Profit growth TTM: 0.0%
Dividend payout: 0.0%

Quarter P&L

Sales latest quarter: ₹45 Cr
Profit latest quarter: ₹1 Cr
YoY quarterly sales growth: -56.3%
YoY quarterly profit growth: -25.5%
OPM latest quarter: 3.0%

Balance Sheet

Book Value: ₹47.3
Face Value: ₹10.0
Total debt: ₹50 Cr
Total cash: ₹1 Cr
Borrowings: ₹50 Cr
Reserves / Equity: 4.4

Cash Flow

Operating cash flow: ₹10 Cr
Free cash flow: -₹2 Cr
FCF yield: -2.1%
Net cash flow: ₹0 Cr

Shareholding

Promoter holding: 42.8%
FII holding: 4.4%
DII holding: 1.5%
Public holding: 51.3%

Peer comparison

Company	Price ₹	P/E	Mkt cap ₹ Cr	Div yield %	Profit qtr ₹ Cr	Profit var %	Sales qtr ₹ Cr	Sales var %	ROCE %
Sun Pharma.Inds.	1,781.00	33.9	4,28,057	0.90	2,901.2	6.0	15,299.9	10.5	20.5
Divi's Lab.	9,588.00	85.5	2,54,665	0.31	902.0	65.5	3,080.0	27.8	22.0
Torrent Pharma.	4,716.20	80.3	1,79,164	0.81	566.0	5.8	4,921.0	54.9	15.2
Zydus Lifesci.	1,153.00	23.6	1,14,963	0.09	990.2	-35.1	8,017.0	22.0	21.1
Laurus Labs	2,052.80	101.3	1,10,699	0.10	362.1	125.5	2,026.3	29.1	17.8
Cipla	1,327.20	29.9	1,06,997	0.98	785.6	-39.2	7,119.3	2.3	15.5
Mankind Pharma	2,500.00	48.7	1,03,876	0.04	574.1	29.6	4,030.6	12.9	13.5
Aarey Drugs	108.81	83.0	346	0.00	1.0	-25.6	44.6	-56.3	5.6
Median	417.90	34.4	2,208	0.07	13.5	29.5	164.0	18.4	15.0

Competes with: Aurobindo Pharma, Cipla, Divi's Laboratories, Dr Reddy's Laboratories, Laurus Labs Limited, Lupin, Mankind Pharma Limited, Sun Pharmaceutical, Torrent Pharmaceuticals, Zydus Lifesciences

Quarterly results

Sales and profit for each of the last 13 quarters. Newest on the right. ₹ crore.

Standalone · to 30 Jun 2026

Line item	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales	51	58	76	210	127	105	134	108	102	84	96	189	45
Expenses	50	56	74	212	126	101	132	112	101	82	98	185	43
Material Cost									93	79	99	179	43
Change in Inventories									4.77	1.59	-2.51	0.10	-1.32
Purchases of Stock-in-Trade									0	0	0	0	0
Employee Cost									0.14	0.19	0.15	0.29	0.16
Other Expenses									2.53	0.85	1.00	5.45	0.98
Operating Profit	1.34	1.84	2.70	-1.44	1.18	3.72	2.20	-4.21	1.71	2.64	-1.51	4.34	1.32
OPM %	2.63	3.18	3.53	-0.68	0.93	3.54	1.64	-3.89	1.67	3.14	-1.57	2.29	2.96
Other Income	0.70	0.84	0.29	5.14	1.58	0.02	0.68	7.54	1.55	0.79	4.18	-0.43	1.72
Exceptional items (within Other Income)								0	0	0	0	0	0
Interest	0.42	0.41	0.47	0.40	0.96	0.49	0.58	1.30	1.04	1.26	0.92	1.78	1.67
Depreciation	0.89	1.27	1.06	1.15	0.47	1.51	0.90	0.41	0.49	0.69	0.83	0.85	0.85
Profit before tax	0.73	1	1.46	2.15	1.33	1.74	1.40	1.62	1.73	1.48	0.92	1.28	0.52
Tax %	0	-22	30	-0.47	6.77	8.62	49	72	21	31	38	-22	-98
Net Profit	0.72	1.23	1.02	2.15	1.24	1.60	0.72	0.47	1.37	1.02	0.57	1.56	1.02
EPS in Rs	0.28	0.48	0.40	0.77	0.44	0.57	0.25	0.17	0.48	0.36	0.20	0.55	0.36
Diluted EPS in Rs								0.04	0.48	0.72	0.20	0.55	0.36

Profit & loss

Yearly sales, costs and profit for 12 years, plus the last 12 months (TTM). ₹ crore.

Standalone · to 31 Mar 2026

Line item	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	213	246	396	349	354	298	348	493	419	396	474	472	415
Expenses	212	245	386	342	347	294	344	481	411	391	471	465	408
Material Cost											473	451
Change in Inventories											-11	3.94
Purchases of Stock-in-Trade											0	0
Employee Cost											0.81	0.76
Other Expenses											8.83	9.83
Operating Profit	1	1	10	8	8	3	5	11	8	4	3	7	7
OPM %	0.60	0.40	2.40	2.20	2.20	1.10	1.30	2.30	1.80	1.10	0.60	1.50	1.60
Other Income	3	3	3	3	4	7	7	3	3	7	10	6	6
Exceptional items (within Other Income)											0	0
Interest	1	2	4	2	2	2	2	2	3	4	4.66	5	6
Depreciation	1	1	1	1	1	1	1	2	2	1.70	1.94	3	3
Profit before tax	1	2	8	8	9	7	8	10	6	5.34	6.10	5	4
Tax %	23	29	31	25	27	20	21	35	37	12	34	27
Net Profit	1	1	5	6	7	6	7	7	4	4.68	4.02	4	4
EPS in Rs	0.65	0.77	3.02	2.64	2.80	2.48	2.78	2.58	1.49	1.67	1.42	1.40	1.47
Diluted EPS in Rs											3.68	1.39
Dividend Payout %	0	0	0	0	4	0	0	0	0	0	0	0

Compounded growth

Average yearly growth over different spans, as stored. A span can cross a demerger or an acquisition.

Compounded sales growth

10 years: 7%
5 years: 6%
3 years: 4%
TTM: -8%

Compounded profit growth

10 years: 12%
5 years: -9%
3 years: 2%
TTM: 0%

Stock price CAGR

10 years: 9%
5 years: 24%
3 years: 34%
1 year: 30%

Return on equity

10 years: 5%
5 years: 4%
3 years: 3%
Last year: 3%

Balance sheet

What the company owns and what it owes, at the end of each year. ₹ crore.

Standalone

Line item	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	17	17	18	23	23	23	23	25	25	28	28	28
Reserves	19	20	31	57	63	69	75	88	92	105	110	122
Borrowings	11	15	10	3	16	18	18	14	38	31	35	50
Other Liabilities	69	74	83	86	43	84	116	117	136	139	117	97
Total Liabilities	115	125	142	170	146	194	233	245	291	303	291	297
Fixed Assets	6	8	12	12	12	12	14	14	14	13	16	26
CWIP	0	0	0	0	0	0	0	0	0	0	0	0
Investments	0	0	0	0	0	0	0	0	0	1	2	2
Other Assets	109	117	130	157	133	181	218	230	277	289	272	269
Total Assets	115	125	142	170	146	194	233	245	291	303	291	297

Cash flows

Real money coming in and going out each year — from the business, from investments and from loans. ₹ crore.

Standalone

Line item	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from Operating Activity	3	6	1	-20	1	3	5	0	-1	-3	10	10
Cash from Investing Activity	-2	-3	-5	-1	-1	-1	-3	-3	0	-2	-6	-12
Cash from Financing Activity	-2	-2	4	23	-2	-2	-2	2	1	6	-4	2
Net Cash Flow	-1	1	-1	2	-3	0	0	-0	1	1	-0	-0
Free Cash Flow	1	3	-4	-21	-1	2	3	-2	-2	-4	4.80	-2

Ratios

How fast customers pay, how long stock sits, and how well capital earns — year by year.

Standalone

Line item	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	114	108	75	100	109	118	170	101	165	170	103	100
Inventory Days	7	3	5	16	23	21	20	11	26	33	36	33
Days Payable	117	108	71	84	40	98	120	86	115	123	81	66
Cash Conversion Cycle	5	3	9	32	92	42	69	26	76	80	58	68
Working Capital Days	49	40	34	69	77	99	91	68	89	106	89	90
ROCE %	7	7	22	14	12	8	9	10	6	6	6	6

Shareholding pattern

Who owns the company — founders (promoters), foreign funds, Indian funds and the public. In %.

Standalone · to 31 Aug 2026

Line item	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Aug 2026
Promoters	50	45	45	45	45	45	45	45	39	38	38	43
FIIs	3.83	3.40	3.40	2.75	2.34	2.34	1.97	1.13	3.86	4.18	4.81	4.41
DIIs	0	0	0	0	0	0	0	0	0	1.62	1.62	1.49
Public	46	51	51	52	53	53	53	54	57	56	56	51
No. of Shareholders	15,269	16,843	16,179	16,676	16,288	16,257	15,796	14,897	14,063	14,188	13,478	13,480

Price trend

The price as a Renko brick chart: small moves drop out so the bigger path stands out.

Change over 1 year +27.7% (₹81.34 → ₹103.89)Brick size ₹4.63 (fixed)Bricks 33

Price moved up one brickPrice moved down one brickLast close ₹103.89 on 8 Oct 2026

Every brick is the same size, about one typical day's move. A new brick needs a full brick's move; turning the other way needs two. Bricks show where the price went, not where it will go.

Open interestPRO

Where option traders are positioned on this stock.

Industry numbers

The numbers that matter most in this industry, from the company's own filings.

1 when an audit qualification is filed as repetitive

0.00flag

2026-03-31

the company's own unlisted debt securities in default at period end

0.00cr

2026-06-30

the company's own loans / revolving facilities in default at period end (standalone filing)

0.00cr

2026-06-30

guarantees / comfort given for promoter, promoter group, directors and KMP

0.00cr

2026-03-31

loans outstanding to promoter, promoter group, directors and KMP (governance filing)

0.00cr

2026-03-31

security given for the borrowing of promoter, promoter group, directors and KMP

0.00cr

2026-03-31

News

News and filings about Aarey Drugs & Pharmaceuticals Limited. Open one to see why it matters.

No recent news for this company.

Supply chain

Who it buys from, sells to and competes with — as recorded in our map of company links.

Competes with

About

What the company is, from our own records: where it sits, where it makes things, and what it is made of.

Sector: Healthcare
Industry: Pharmaceuticals
Classification: Healthcare › Pharmaceuticals
ISIN: INE198H01019

Plants

Aarey Drugs Tarapur plant

News impact

Big market events that reach Aarey Drugs & Pharmaceuticals Limited, and how the effect spreads.

No recent market events reach this company.

Dividends, splits & big trades

Money paid out, share splits and buybacks, and big buys or sells by funds and insiders.

Splits, bonuses & buybacks

daily-prices repair: 7 rows from NSE's archive (replace 2, delete 0, insert 5), 2023-11-12..2026-02-01 (docs/flat_day_repair.md)1× · 12 Nov 2023
bse-history fill: 1383 BSE bars before cutoff, code 524412, seam residual 1.00121× · 6 Aug 2021

Bulk & block deals

Date	Who	Bought / sold	Shares	Price
7 Oct 2026	VAYUMIND INNOVATIONS PRIVATE LIMITED	BUY	1,81,007	₹109.00
7 Oct 2026	AMZEN FINANCIAL SERVICES PRIVATE LIMITED	SELL	1,81,006	₹109.00
30 Sep 2026	ARYA RAVI MANIRAM	BUY	1,44,423	₹100.01
28 Aug 2026	VAYUMIND INNOVATIONS PRIVATE LIMITED	BUY	2,74,415	₹88.97
26 Aug 2026	VAYUMIND INNOVATIONS PRIVATE LIMITED	BUY	1,54,471	₹80.45
4 Aug 2026	SHREE SALASAR PROPERTIES & FIN.(P)LTD.	BUY	2,00,000	₹84.00
17 Apr 2026	SHAH SANJAY JAYKANT	BUY	1,50,000	₹81.51

Documents

Annual reports, results presentations and earnings calls, straight from the source.

Annual report · 2024-256 Sep 2025

Facts from company filings and exchange data. Not investment advice: nothing here tells you to buy or sell.